JP2017504637A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504637A5 JP2017504637A5 JP2016549143A JP2016549143A JP2017504637A5 JP 2017504637 A5 JP2017504637 A5 JP 2017504637A5 JP 2016549143 A JP2016549143 A JP 2016549143A JP 2016549143 A JP2016549143 A JP 2016549143A JP 2017504637 A5 JP2017504637 A5 JP 2017504637A5
- Authority
- JP
- Japan
- Prior art keywords
- solvent
- apis
- excipients
- particle size
- api
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 28
- 239000008186 active pharmaceutical agent Substances 0.000 claims 25
- 239000002904 solvent Substances 0.000 claims 19
- 239000002245 particle Substances 0.000 claims 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims 13
- 239000000725 suspension Substances 0.000 claims 7
- 238000009826 distribution Methods 0.000 claims 5
- 230000032683 aging Effects 0.000 claims 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 2
- 238000004821 distillation Methods 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 1
- 229930183010 Amphotericin Natural products 0.000 claims 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940009444 amphotericin Drugs 0.000 claims 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000012296 anti-solvent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- 238000000498 ball milling Methods 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 229960003728 ciclesonide Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229960003722 doxycycline Drugs 0.000 claims 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 229960000289 fluticasone propionate Drugs 0.000 claims 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 1
- 229960000308 fosfomycin Drugs 0.000 claims 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 229960001888 ipratropium Drugs 0.000 claims 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000005374 membrane filtration Methods 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 229960004023 minocycline Drugs 0.000 claims 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- 238000010951 particle size reduction Methods 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 1
- 229960001225 rifampicin Drugs 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 229960000195 terbutaline Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940110309 tiotropium Drugs 0.000 claims 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims 1
- 229960000257 tiotropium bromide Drugs 0.000 claims 1
- 229960000707 tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT107433 | 2014-01-28 | ||
| PT10743314A PT107433B (pt) | 2014-01-28 | 2014-01-28 | Processo de redução e controlo do tamanho de partícula |
| PCT/GB2015/050186 WO2015114320A1 (en) | 2014-01-28 | 2015-01-27 | Assisted particle size reduction process |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504637A JP2017504637A (ja) | 2017-02-09 |
| JP2017504637A5 true JP2017504637A5 (enExample) | 2018-02-22 |
| JP6499187B2 JP6499187B2 (ja) | 2019-04-10 |
Family
ID=52450514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549143A Expired - Fee Related JP6499187B2 (ja) | 2014-01-28 | 2015-01-27 | 支援された粒子径低減方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10328027B2 (enExample) |
| EP (1) | EP3096738B1 (enExample) |
| JP (1) | JP6499187B2 (enExample) |
| AU (1) | AU2015212618B2 (enExample) |
| CA (1) | CA2938071A1 (enExample) |
| DK (1) | DK3096738T3 (enExample) |
| ES (1) | ES2702643T3 (enExample) |
| HU (1) | HUE041329T2 (enExample) |
| IL (1) | IL246989A0 (enExample) |
| PT (1) | PT107433B (enExample) |
| WO (1) | WO2015114320A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
| US20060140984A1 (en) | 2002-10-25 | 2006-06-29 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
| US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
| US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
| WO2009090495A2 (en) | 2007-12-07 | 2009-07-23 | Foamix Ltd. | Oil and liquid silicone foamable carriers and formulations |
| US20120087872A1 (en) | 2009-04-28 | 2012-04-12 | Foamix Ltd. | Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof |
| WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| WO2011013008A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| EP2482788B1 (en) | 2009-10-02 | 2022-12-14 | Journey Medical Corporation | Topical tetracycline compositions |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| PT108368B (pt) | 2015-03-31 | 2018-11-05 | Hovione Farm S A | Produção contínua de partículas |
| PT109117B (pt) * | 2016-01-28 | 2019-02-01 | Hovione Farm Sa | Complexação de ingredientes ativos farmacêuticos |
| IL285928B2 (en) | 2016-05-06 | 2025-06-01 | Eagle Pharmaceuticals Inc | Fulvestrant formulations and methods of their use |
| US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
| CN110361307B (zh) * | 2019-08-15 | 2022-04-01 | 安徽工程大学 | 一种利用粒度分布特征值判断稻米新陈度的方法 |
| EP3868842B1 (en) | 2020-02-19 | 2023-06-07 | University of Limerick | Particle coating method |
| GB202002325D0 (en) | 2020-02-19 | 2020-04-01 | Univ Limerick | Particle coating method |
| WO2022170027A1 (en) * | 2021-02-04 | 2022-08-11 | Edenbridge Pharmaceuticals, LLC | Inhaled ivermectin |
| IL309073A (en) | 2021-06-03 | 2024-02-01 | Arcadia Medicine Inc | Enantiomeric entactogen compounds and methods of their use. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008411D0 (en) * | 2000-04-05 | 2000-05-24 | Vectura Ltd | Pharmaceutical preparations and their manufacture |
| GB0016040D0 (en) | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
| US6379459B1 (en) * | 2000-10-24 | 2002-04-30 | The United States Of America As Represented By The Secretary Of The Interior | Crystallization of powders having uniform particle sizes by Ostwald ripening at large levels of supersaturation |
| CN101453986A (zh) | 2006-03-14 | 2009-06-10 | 默克公司 | 通过微研磨和在微晶种上结晶生产结晶有机微粒组合物的方法和设备及其应用 |
| EP2077903A2 (en) * | 2006-10-03 | 2009-07-15 | Ranbaxy Laboratories, Ltd. | Process for the preparation of form i and form ii of ritonavir |
| EP2050437A1 (en) * | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
| CA2707594C (en) | 2007-12-13 | 2015-08-18 | Novartis Ag | Process for preparing particulates of crystalline drug substance |
| PT105058B (pt) * | 2010-04-21 | 2013-04-17 | Hovione Farmaciencia S A | Processo para processamento de partículas de ingredientes activos farmacêuticos |
| PT106237B (pt) * | 2012-03-30 | 2015-03-19 | Hovione Farmaci Ncia S A | Produção de partículas substancialmente monodispersas utilizando moagem e separação por membranas |
-
2014
- 2014-01-28 PT PT10743314A patent/PT107433B/pt active IP Right Grant
-
2015
- 2015-01-27 AU AU2015212618A patent/AU2015212618B2/en not_active Ceased
- 2015-01-27 WO PCT/GB2015/050186 patent/WO2015114320A1/en not_active Ceased
- 2015-01-27 US US15/115,193 patent/US10328027B2/en not_active Expired - Fee Related
- 2015-01-27 HU HUE15702834A patent/HUE041329T2/hu unknown
- 2015-01-27 ES ES15702834T patent/ES2702643T3/es active Active
- 2015-01-27 JP JP2016549143A patent/JP6499187B2/ja not_active Expired - Fee Related
- 2015-01-27 CA CA2938071A patent/CA2938071A1/en not_active Abandoned
- 2015-01-27 EP EP15702834.1A patent/EP3096738B1/en not_active Not-in-force
- 2015-01-27 DK DK15702834.1T patent/DK3096738T3/en active
-
2016
- 2016-07-28 IL IL246989A patent/IL246989A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504637A5 (enExample) | ||
| JP2017019845A5 (enExample) | ||
| CN102970978B (zh) | 活性药物成分的颗粒加工方法 | |
| JP6499187B2 (ja) | 支援された粒子径低減方法 | |
| JP7331067B2 (ja) | ５－アミノ－２，３－ジヒドロフタラジン－１，４－ジオンの結晶形 | |
| JP2013525338A5 (enExample) | ||
| JP6949856B2 (ja) | ５−アミノ−２，３−ジヒドロフタラジン−１，４−ジオンの結晶形の製造方法 | |
| JP7446226B2 (ja) | ５－アミノ－２，３－ジヒドロ－１，４－フタラジンジオンの可溶化方法 | |
| CN115916258A (zh) | 糖皮质激素减量剂 | |
| CN110392568A (zh) | N-乙酰半胱氨酸的制剂及其用途 | |
| CN115052602A (zh) | 5-胺基-2,3-二氢-1,4-酞嗪二酮在治疗罕见的慢性发炎性肺病中的用途 | |
| CA2587393A1 (en) | Pharmaceutical manufacturing process | |
| CN105193832A (zh) | 一种治疗肺病的药物组合物 | |
| RU2582297C1 (ru) | Лекарственное средство, обладающее гипохолестеринемическим, гиполипидемическим действием | |
| HK40001510B (en) | Method for producing a crystalline form of 5-amino-2, 3-dihydrophthalazine-1, 4-dione | |
| HK40001511A (en) | Crystalline form of 5-amino-2,3-dihydrophtalazine-1,4-dione | |
| HK40010471A (en) | Formulations of n-acetylcysteine and uses thereof |